Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04974606 · ClinicalTrials.gov registry record · NA
Effect of Coffeeberry on Mood, Motivation and Cognitive Performance
A NA study, sponsored by PepsiCo Global R&D.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04974606: Completed NA study, sponsored by PepsiCo Global R&D.
NCT04974606 is a NA study that has completed, run by PepsiCo Global R&D. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04974606, a NA study, has completed, sponsored by PepsiCo Global R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary purpose is to test the short-term effects of the acute consumption of two novel beverages made from coffeeberries, the fruit of the coffee plant (Coffea arabica) benchmarked against caffeine on several aspects of cognitive performance. Preliminary studies suggest that flavanols and chlorogenic acids can enhance cognitive performance. It is unknown if drinks formulated with flavanols and chlorogenic acids (without high sugar or caffeine) improve cognition or mood to a similar extent as caffeine. Coffeeberry beverage comparisons will be made to a flavored positive control beverage containing caffeine and a flavored placebo beverage.
Primary Outcome
Objective Cognitive Demand Battery (CDB) using Computerised Mental Performance Assessment framework tasks (COMPASS) for word and picture presentation and recall, serial 3 and 7 subtraction, Rapid Visual Information Processing (RVIP).
Interventions
- DIETARY_SUPPLEMENT Cherry-flavored still beverage
- OTHER Placebo cherry-flavored still beverage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-06-28 |
| Est. Completion | 2016-12-16 |
| Phase | NA |
What the finished NCT04974606 record still lists
NCT04974606 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Cherry-flavored still beverage is the first listed.
NCT04974606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04974606 about?
NCT04974606 is a clinical study titled "Effect of Coffeeberry on Mood, Motivation and Cognitive Performance". The primary purpose is to test the short-term effects of the acute consumption of two novel beverages made from coffeeberries, the fruit of the coffee plant (Coffea arabica) benchmarked against caffeine on several aspects of cognitive performance. Preliminary studies suggest that flavanols and chlo...
What is the current status of trial NCT04974606?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-06-28. Estimated completion is 2016-12-16.
What interventions are being tested in trial NCT04974606?
The interventions under investigation include: Cherry-flavored still beverage (DIETARY_SUPPLEMENT), Placebo cherry-flavored still beverage (OTHER).
Who is sponsoring clinical trial NCT04974606?
This trial is sponsored by PepsiCo Global R&D, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04974606's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI